Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

Blood

Volumn 117, Issue 1, 2011, Pages 72-82

  Lamers, Cor H J ^a   Willemsen, Ralph ^a   Van Elzakker, Pascal ^a   Van Steenbergen Langeveld, Sabine ^a   Broertjes, Marieke ^a   Oosterwijk Wakka, Jeannette ^b   Oosterwijk, Egbert ^b   Sleijfer, Stefan ^a   Debets, Reno ^a   Gratama, Jan W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CHIMERIC ANTIBODY; CHIMERIC ANTIBODY RECEPTOR; CORTICOSTEROID; EPITOPE; GIRENTUXIMAB; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; GENE TARGETING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; KIDNEY CARCINOMA; LOW DRUG DOSE; MEDIATOR; PRIORITY JOURNAL; PROTEIN DOMAIN; RETROVIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 78650969008     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294520     Document Type: Article

References (49)

1. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
2. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-6115.
3. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
4. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
5. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271.
6. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215-223.
7. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
8. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
9. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-e22.
10. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther. 2010;10(4):547-562.
11. Fontana R, Bregni M, Cipponi A, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood. 2009;113(8):1651-1660.
12. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107(6):2294-2302.
13. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2(2):216-223.
14. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708-4715.
15. Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH. Single chain Ig/gamma genere-directed human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol. 1996;157(2):836-843.
16. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38(4):489-494.
17. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85(6):865-870.
18. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 1998;5(9):1195-1203.
19. Lamers CH, Willemsen RA, van Elzakker P, van Krimpen BA, Gratama JW, Debets R. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 2006;13(5):503-509.
20. Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 2002;9(7):613-623.
21. Lamers CH, van Elzakker P, Langeveld SC, Sleijfer S, Gratama JW. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy. 2006;8(6):542-553.
22. Steffens MG, Boerman OC, Oyen WJ, et al. Intra-tumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res. 1999;59(7):1615-1619.
23. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(10 Suppl):3268s-3274s.
24. Lamers CH, Gratama JW, Pouw NM, et al. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum Gene Ther. 2005;16(12):1452-1462.
25. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother. 2007;56(12):1875-1883.
26. Uemura H, Okajima E, Debruyne FMJ, Oosterwijk E. Internal image antiidiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer. 1994;56(4):609-614.
27. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004;90(5):985-990.
28. Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer- specific chimeric single chain and two chain TCR. Gene Ther. 2000;7(16):1369-1377.
29. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-219.
30. Larsen MV, Lundegaard C, Lamberth K, et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol. 2005;35(8):2295-2303.
31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152(1):163-175.
32. Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol. 2000;7(1-2):203-214.
33. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-3402.
34. Altschul SF, Wootton JC, Gertz EM, et al. Protein database searches using compositionally adjusted substitution matrices. FEBS J. 2005;272(20):5101-5109.
35. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245-1256.
36. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-α-2a in metastatic renal cell carcinoma patients [published online ahead of print May 30, 2010]. World J Urol. doi:10.1007/s00345-010-0570-2.
37. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23(27):6540- 6548.
38. Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood. 2003;101(12):4930-4936.
39. Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV. Minimizing the immunogenicity of antibodies for clinical application. Tumour Biol. 2005;26(1):31-43.
40. Kim KS, Kim HJ, Han BW, Myung PK, Hong HJ. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization. Biochem Biophys Res Commun. 2010;396(2):231-237.
41. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8(21):1601-1608.
42. Onion D, Patel P, Pineda RG, James N, Mautner V. Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Hum Gene Ther. 2009;20(11):1249-1258.
43. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther. 2009;16(6):473-488.
44. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther. 2007;7(5):325-333.
45. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-422.
46. Mingozzi F, High KA. Immune responses toAAV in clinical trials. Curr Gene Ther. 2007;7(5):316-324.
47. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008;118(3):1099- 1109.
48. Rolland M, Heckerman D, Deng W, et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One. 2008;3(1):e1424.
49. Choppin J, Cohen W, Bianco A, et al. Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol. 2001;166(10):6164-6169.